Mattias Mandorfer
Overview
Explore the profile of Mattias Mandorfer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
275
Citations
3091
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Bernhard J, Schwarz M, Balcar L, Hofer B, Dominik N, Strassl R, et al.
Sci Rep
. 2024 Oct;
14(1):25921.
PMID: 39472518
Current guidelines recommend reflex testing for hepatitis D virus (HDV) coinfection in hepatitis B surface antigen (HBsAg)-positive patients over risk-factor based screening. We aimed to evaluate the feasibility and diagnostic...
12.
Semmler G, Balcar L, Simbrunner B, Hartl L, Jachs M, Schwarz M, et al.
JHEP Rep
. 2024 Oct;
6(11):101169.
PMID: 39444411
Background & Aims: The LiverRisk score has been proposed as a blood-based tool to estimate liver stiffness measurement (LSM), thereby stratifying the risk of compensated advanced chronic liver disease (cACLD,...
13.
Fromme M, Payance A, Mandorfer M, Thorhauge K, Pons M, Miravitlles M, et al.
Gastroenterology
. 2024 Oct;
168(2):367-381.
PMID: 39414159
Background & Aims: Homozygous Pi∗Z mutation in alpha-1 antitrypsin (Pi∗ZZ genotype) predisposes to pulmonary loss-of-function and hepatic gain-of-function injury. To facilitate selection into clinical trials typically targeting only 1 organ,...
14.
Dominik N, Balcar L, Semmler G, Simbrunner B, Schwarz M, Hofer B, et al.
Aliment Pharmacol Ther
. 2024 Oct;
60(10):1497-1498.
PMID: 39380454
No abstract available.
15.
Balcar L, Schwarz M, Dorn L, Jachs M, Hartl L, Weseslindtner L, et al.
Liver Int
. 2024 Oct;
44(12):3151-3163.
PMID: 39351692
Background And Aims: Identification of people living with hepatitis C virus (HCV) via readily available laboratory records could be a key strategy for macro-elimination, aligning with the WHO elimination goal....
16.
Hofer B, Simbrunner B, Konigshofer P, Brusilovskaya K, Petrenko O, Taru V, et al.
Dig Liver Dis
. 2024 Sep;
57(2):450-458.
PMID: 39343656
Background: Cirrhosis is associated with a proinflammatory environment. Aims: To analyse aetiology-specific inflammation patterns in compensated cirrhosis in animal models and patients. Methods: Portal pressure (PP), fibrosis (collagen proportionate area...
17.
Jachs M, Odriozola A, Turon F, Moga L, Tellez L, Fischer P, et al.
Lancet Gastroenterol Hepatol
. 2024 Sep;
9(12):1111-1120.
PMID: 39326431
Background: In patients with compensated advanced chronic liver disease (cACLD), risk of clinically significant portal hypertension (CSPH) can be estimated by applying non-invasive tests such as liver stiffness measurement (LSM),...
18.
Hartl L, Schwarz M, Simbrunner B, Jachs M, Wolf P, Bauer D, et al.
Aliment Pharmacol Ther
. 2024 Sep;
61(1):88-98.
PMID: 39305115
Background And Aims: We aimed to characterise insulin-like growth factor-1 (IGF-1) signalling in patients with advanced chronic liver disease (ACLD). Methods: Consecutive patients undergoing hepatic venous pressure gradient [HVPG] measurement...
19.
Magaz M, Giudicelli-Lett H, Abraldes J, Nicoara-Farcau O, Turon F, Rajoriya N, et al.
J Hepatol
. 2024 Aug;
82(1):72-83.
PMID: 39181213
Background & Aims: Current knowledge of the natural history of patients with porto-sinusoidal vascular disorder (PSVD) is derived from small studies. The aim of the present study was to determine...
20.
Schwarz M, Simbrunner B, Jachs M, Hartl L, Balcar L, Bauer D, et al.
Liver Int
. 2024 Aug;
44(11):2904-2914.
PMID: 39136222
Background And Aims: The role of histamine in advanced chronic liver disease (ACLD) is poorly understood. We investigated plasma histamine levels across ACLD stages and their prognostic value. Methods: We...